MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Abbott Laboratories

Închisă

SectorSănătate

128.47 1.01

Rezumat

Modificarea prețului

24h

Curent

Minim

128.47

Maxim

129.22

Indicatori cheie

By Trading Economics

Venit

454M

1.8B

Vânzări

784M

11B

P/E

Medie Sector

16.484

36.442

EPS

1.26

Randament dividend

1.75

Marjă de profit

15.967

Angajați

114,000

EBITDA

383M

3B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+14.07% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.75%

3.00%

Data viitoare de dividende

17 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-1B

229B

Deschiderea anterioară

127.46

Închiderea anterioară

128.47

Sentimentul știrilor

By Acuity

57%

43%

296 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Abbott Laboratories Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 oct. 2025, 12:02 UTC

Câștiguri

Abbott Labs Posts Higher 3Q Sales, Reaffirms Outlook

17 iul. 2025, 12:10 UTC

Câștiguri

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

15 oct. 2025, 16:15 UTC

Câștiguri

Abbott Stock Drops Despite Earnings. Baby-Formula Sales Took a Hit. -- Barrons.com

15 oct. 2025, 12:25 UTC

Câștiguri

Abbott Posts Solid Earnings, Adult Nutrition Drives Sales. The Stock Drops Anyway. -- Barrons.com

15 oct. 2025, 11:32 UTC

Câștiguri

Abbott Labs Still Sees 2025 Organic Sales Up 6%-7% Including Covid-19 Testing-Related Sales >ABT

15 oct. 2025, 11:32 UTC

Câștiguri

Abbott Labs Still Sees 2025 Organic Sales Up 7.5%-8% Excluding Covid-19 Testing-Related Sales >ABT

15 oct. 2025, 11:31 UTC

Câștiguri

Abbott Labs Sees 2025 Adj EPS $5.12-Adj EPS $5.18 >ABT

15 oct. 2025, 11:30 UTC

Câștiguri

Abbott Labs 3Q Adjusted Operating Margin 23% >ABT

15 oct. 2025, 11:30 UTC

Câștiguri

Abbott Labs Reaffirms Full-Year Guidance >ABT

15 oct. 2025, 11:30 UTC

Câștiguri

Abbott Labs 3Q Organic Sales Growth Up 5.5% >ABT

15 oct. 2025, 11:30 UTC

Câștiguri

Abbott Labs 3Q Sales $11.37B >ABT

15 oct. 2025, 11:30 UTC

Câștiguri

Abbott Labs 3Q Adj EPS $1.30 >ABT

15 oct. 2025, 11:30 UTC

Câștiguri

Abbott Labs 3Q Net $1.64B >ABT

15 oct. 2025, 11:30 UTC

Câștiguri

Abbott Labs 3Q EPS 94c >ABT

11 oct. 2025, 00:18 UTC

Achiziții, Fuziuni, Preluări

Why Biotech May Be Back -- Barrons.com

17 iul. 2025, 13:14 UTC

Câștiguri

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 iul. 2025, 12:16 UTC

Câștiguri

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 iul. 2025, 11:32 UTC

Câștiguri

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

17 iul. 2025, 11:32 UTC

Câștiguri

Abbott Labs: See Momentum Carrying Into 2026 >ABT

17 iul. 2025, 11:31 UTC

Câștiguri

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q Sales $11.14B >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q Net $1.78B >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q Adj EPS $1.26 >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

17 iul. 2025, 11:30 UTC

Câștiguri

Abbott Labs 2Q EPS $1.01 >ABT

17 iul. 2025, 09:08 UTC

Acțiuni populare

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

Comparație

Modificare preț

Abbott Laboratories Așteptări

Obiectiv de preț

By TipRanks

14.07% sus

Prognoză pe 12 luni

Medie 146.63 USD  14.07%

Maxim 162 USD

Minim 136 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAbbott Laboratories - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

18

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

132.82 / 134.43Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Neutral Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

296 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
help-icon Live chat